The SENS Foundation Research Center is our internal facility for proof-of-concept research in rejuvenation biotechnologies. Find out more or make a donation to help our work.
SENS Foundation works to develop, promote and ensure widespread access to rejuvenation biotechnologies which comprehensively address the disabilities and diseases of aging.
The Foundation catalyses progress toward a comprehensive panel of rejuvenation biotechnologies through its growing global networks and collaborations, and through key research projects, executed in its own Research Center and numerous affiliated universities, research organizations and other centers of excellence.
Recent news, events and blog posts
Welcome to the Academic Initiative's New Site
January 3, 2012 by Daniel Kimbel from Academic Initiative
Welcome to the SENS Foundation Academic Initiative’s new website. In addition to containing more comprehensive information about the Initiative and what it does, this site offers a number of new features, including a listing of outreach projects and a searchable database of member profiles. The site leaves plenty of room for the Initiative to grow into, thanks to its new committee pages, its new media section, and its more streamlined navigation.
NFT-Specific Tau Vaccine Arrests Tangle Progress
January 1, 2012 by Michael Rae from Chief Science Officer's Team
Immunotherapy targeting the age-related accumulation of extracellular aggregates, in the form of ß-amyloid, is the first rejuvenation biotechnology to reach Phase III human clinical trials.
Holiday Appeal
$30,000 in Academic Initiative Grants
December 7, 2011 by Daniel Kimbel from Academic Initiative
The SENS Foundation Academic Initiative is pleased to announce that it will be awarding up to $30,000 in materials grants in 2012. These grants are available to undergraduate, graduate, and medical students, and may be used to cover the cost of laboratory materials for aging- and rejuvenation-related research projects. A typical grant will range from $500-$2000, but grants of up to $5000 may be awarded for group projects.
How to Disable a Cellular Bomb: Findings and Tools on the Machinery of ALT
December 2, 2011 by Michael Rae from Chief Science Officer's Team
Research Advisors
Alexandra Stolzing
Group Leader, Stem Cell Biology and Regeneration, Fraunhofer Institute
External News
-
Embryonic stem cell trials for macular degeneration
-
at The Lancet
-
Researchers Target, Clear Senescent Cells in Mice
-
at Nature
- Age-Related Diseases: Medicine's Final Adversary? -
- Regenerative Medicine Institute to continue getting state funds -
-
Lab-grown brain cells should aid research into Alzheimer's
-
at BBC News
Video
Mike Kope's closing speech at SENS5: SENS Foundation's progress and future goals.
Dr Aubrey de Grey on CNN's global health show Vital Signs.
